Performance &

Progress

Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs. Paradigm is currently developing pentosan polysulfate sodium (PPS), an FDA-approved drug that has a long track record of safely treating inflammation over 60 years. Paradigm’s primary focus is to develop PPS (under the name Zilosul®) to treat osteoarthritis (OA), with an addressable population of over 72m in key markets (US, EU5, AU, CAN).

Want more details about our development pipeline?

Current shareholders: want to access and update your personal details?

Capital Raise Documentation
ASX:PAR
_ _0.00

0.00

0.00%

Prev. close

Volume

 $0.00

0

Open

High

Low

 $0.00

$0.00

$0.00

Powered by Share Link

Last updated – 

Next Investor Event

Last updated 28/10/22 3:45pm

ASX Performance

ASX Performance

Market Reports